vs

Side-by-side financial comparison of Canaan Inc. (CAN) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

OptimizeRx Corp is the larger business by last-quarter revenue ($32.2M vs $20.8M, roughly 1.6× Canaan Inc.). OptimizeRx Corp runs the higher net margin — 15.6% vs -18.4%, a 34.0% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

CAN vs OPRX — Head-to-Head

Bigger by revenue
OPRX
OPRX
1.6× larger
OPRX
$32.2M
$20.8M
CAN
Higher net margin
OPRX
OPRX
34.0% more per $
OPRX
15.6%
-18.4%
CAN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CAN
CAN
OPRX
OPRX
Revenue
$20.8M
$32.2M
Net Profit
$-3.8M
$5.0M
Gross Margin
99.9%
74.8%
Operating Margin
-15.9%
26.6%
Net Margin
-18.4%
15.6%
Revenue YoY
-0.2%
Net Profit YoY
6535.9%
EPS (diluted)
$-0.05
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
OPRX
OPRX
Q4 25
$20.8M
$32.2M
Q3 25
$13.8M
$26.1M
Q2 25
$11.4M
$29.2M
Q1 25
$21.9M
Q4 24
$32.3M
Q3 24
$10.2M
$21.3M
Q2 24
$4.8M
$18.8M
Q1 24
$19.7M
Net Profit
CAN
CAN
OPRX
OPRX
Q4 25
$-3.8M
$5.0M
Q3 25
$-1.5M
$779.0K
Q2 25
$-11.9M
$1.5M
Q1 25
$-2.2M
Q4 24
$-78.0K
Q3 24
$-10.4M
$-9.1M
Q2 24
$-5.4M
$-4.0M
Q1 24
$-6.9M
Gross Margin
CAN
CAN
OPRX
OPRX
Q4 25
99.9%
74.8%
Q3 25
99.9%
67.2%
Q2 25
99.9%
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
99.9%
63.1%
Q2 24
99.8%
62.2%
Q1 24
62.0%
Operating Margin
CAN
CAN
OPRX
OPRX
Q4 25
-15.9%
26.6%
Q3 25
-27.0%
7.9%
Q2 25
-45.5%
10.9%
Q1 25
-9.6%
Q4 24
11.2%
Q3 24
-77.2%
-40.2%
Q2 24
-193.9%
-19.9%
Q1 24
-25.5%
Net Margin
CAN
CAN
OPRX
OPRX
Q4 25
-18.4%
15.6%
Q3 25
-11.0%
3.0%
Q2 25
-104.4%
5.2%
Q1 25
-10.0%
Q4 24
-0.2%
Q3 24
-102.7%
-42.8%
Q2 24
-112.3%
-21.3%
Q1 24
-35.0%
EPS (diluted)
CAN
CAN
OPRX
OPRX
Q4 25
$-0.05
$0.27
Q3 25
$-0.02
$0.04
Q2 25
$-0.25
$0.08
Q1 25
$-0.12
Q4 24
$0.00
Q3 24
$-0.50
Q2 24
$-0.22
Q1 24
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$23.4M
Total DebtLower is stronger
$6.2M
$26.3M
Stockholders' EquityBook value
$52.4M
$128.3M
Total Assets
$92.5M
$176.9M
Debt / EquityLower = less leverage
0.12×
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
OPRX
OPRX
Q4 25
$23.4M
Q3 25
$19.5M
Q2 25
$16.6M
Q1 25
$16.6M
Q4 24
$13.4M
Q3 24
$16.1M
Q2 24
Q1 24
Total Debt
CAN
CAN
OPRX
OPRX
Q4 25
$6.2M
$26.3M
Q3 25
$6.2M
$28.8M
Q2 25
$6.2M
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Q1 24
$37.8M
Stockholders' Equity
CAN
CAN
OPRX
OPRX
Q4 25
$52.4M
$128.3M
Q3 25
$44.7M
$122.3M
Q2 25
$33.8M
$119.3M
Q1 25
$116.3M
Q4 24
$117.0M
Q3 24
$43.6M
$114.5M
Q2 24
$56.8M
$121.0M
Q1 24
$122.5M
Total Assets
CAN
CAN
OPRX
OPRX
Q4 25
$92.5M
$176.9M
Q3 25
$81.7M
$170.3M
Q2 25
$78.0M
$169.3M
Q1 25
$167.8M
Q4 24
$171.2M
Q3 24
$69.3M
$165.2M
Q2 24
$73.7M
$172.9M
Q1 24
$176.4M
Debt / Equity
CAN
CAN
OPRX
OPRX
Q4 25
0.12×
0.20×
Q3 25
0.14×
0.24×
Q2 25
0.18×
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×
Q1 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
OPRX
OPRX
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
$7.1M
FCF MarginFCF / Revenue
22.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
OPRX
OPRX
Q4 25
$7.1M
Q3 25
$3.2M
Q2 25
$4.6M
Q1 25
$3.9M
Q4 24
$198.0K
Q3 24
$1.8M
Q2 24
$782.0K
Q1 24
$2.1M
Free Cash Flow
CAN
CAN
OPRX
OPRX
Q4 25
$7.1M
Q3 25
$3.2M
Q2 25
$4.6M
Q1 25
$3.8M
Q4 24
$181.0K
Q3 24
$1.8M
Q2 24
$737.0K
Q1 24
$2.1M
FCF Margin
CAN
CAN
OPRX
OPRX
Q4 25
22.0%
Q3 25
12.2%
Q2 25
15.6%
Q1 25
17.5%
Q4 24
0.6%
Q3 24
8.3%
Q2 24
3.9%
Q1 24
10.6%
Capex Intensity
CAN
CAN
OPRX
OPRX
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.1%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
CAN
CAN
OPRX
OPRX
Q4 25
1.41×
Q3 25
4.11×
Q2 25
2.98×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons